Abstract
Objective: To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS).
Methods: Patients aged 18–65 years with a diagnosis of MS, a stable disability level ≤6 on the Kurtzke extended disability status scale (EDSS), and a mean score >4 on the fatigue severity scale (FSS) were eligible for the 9 week, single blind, phase 2, two centre study. Exclusion criteria included a diagnosis of narcolepsy, sleep apnoea, or clinically significant major systemic disease and recent use of medications affecting fatigue. All patients, who remained blinded for the treatment regimen, received placebo during weeks 1–2, 200 mg/day modafinil during weeks 3–4, 400 mg/day modafinil during weeks 5–6, and placebo during weeks 7–9. Safety was evaluated by unblinded investigators. Efficacy was evaluated by self rating scales, using the FSS, the modified fatigue impact scale (MFIS), a visual analogue scale for fatigue (VAS-F), and the Epworth sleepiness scale (ESS). Adverse events were recorded.
Results: Seventy two patients (MS type: 74% relapsing-remitting; 7% primary progressive; 19% secondary progressive) received treatment. After treatment with 200 mg/day modafinil for 2 weeks, a significant improvement in fatigue versus placebo run in was demonstrated. Mean scores after treatment with 200 mg/day modafinil were: FSS, 4.7 versus 5.5 for placebo (p<0.001); MFIS, 37.7 versus 44.7 (p<0.001); and VAS-F, 5.4 versus 4.5 (p=0.003). Fatigue scores for 400 mg/day modafinil were not significantly improved versus placebo run in. Mean ESS scores were significantly improved (p<0.001) with 200 mg/day modafinil (7.2) and 400 mg/day (7.0) versus the score at baseline (9.5). Serious adverse events were not found at either dose. The most common adverse events were headache, nausea, and aesthenia. Sixty five patients (90%) completed the study.
Conclusions: These data suggest that 200 mg/day modafinil significantly improves fatigue and is well tolerated in patients with MS.
Full Text
The Full Text of this article is available as a PDF (113.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beusterien K. M., Rogers A. E., Walsleben J. A., Emsellem H. A., Reblando J. A., Wang L., Goswami M., Steinwald B. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999 Sep 15;22(6):757–765. doi: 10.1093/sleep/22.6.757. [DOI] [PubMed] [Google Scholar]
- Broughton R. J., Fleming J. A., George C. F., Hill J. D., Kryger M. H., Moldofsky H., Montplaisir J. Y., Morehouse R. L., Moscovitch A., Murphy W. F. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997 Aug;49(2):444–451. doi: 10.1212/wnl.49.2.444. [DOI] [PubMed] [Google Scholar]
- Cohen R. A., Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol. 1989 Jun;46(6):676–680. doi: 10.1001/archneur.1989.00520420096030. [DOI] [PubMed] [Google Scholar]
- Fisk J. D., Pontefract A., Ritvo P. G., Archibald C. J., Murray T. J. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994 Feb;21(1):9–14. [PubMed] [Google Scholar]
- Freal J. E., Kraft G. H., Coryell J. K. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984 Mar;65(3):135–138. [PubMed] [Google Scholar]
- Johns M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540–545. doi: 10.1093/sleep/14.6.540. [DOI] [PubMed] [Google Scholar]
- Krupp L. B., Coyle P. K., Doscher C., Miller A., Cross A. H., Jandorf L., Halper J., Johnson B., Morgante L., Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995 Nov;45(11):1956–1961. doi: 10.1212/wnl.45.11.1956. [DOI] [PubMed] [Google Scholar]
- Krupp L. B., LaRocca N. G., Muir-Nash J., Steinberg A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121–1123. doi: 10.1001/archneur.1989.00520460115022. [DOI] [PubMed] [Google Scholar]
- Krupp L. B., Pollina D. A. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996 Dec;9(6):456–460. doi: 10.1097/00019052-199612000-00011. [DOI] [PubMed] [Google Scholar]
- Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
- Murray T. J. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985 Aug;12(3):251–254. doi: 10.1017/s0317167100047107. [DOI] [PubMed] [Google Scholar]
- Nicolaidis S., De Saint Hilaire Z. Nonamphetamine awakening agent modafinil induces feeding changes in the rat. Brain Res Bull. 1993;32(2):87–90. doi: 10.1016/0361-9230(93)90060-o. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Chen S. Y., Clift S. J., Dahlitz M. J., Dunn G. The clinical diagnosis of the narcoleptic syndrome. J Sleep Res. 1998 Mar;7(1):41–52. doi: 10.1046/j.1365-2869.1998.00093.x. [DOI] [PubMed] [Google Scholar]
- Vercoulen J. H., Hommes O. R., Swanink C. M., Jongen P. J., Fennis J. F., Galama J. M., van der Meer J. W., Bleijenberg G. The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol. 1996 Jul;53(7):642–649. doi: 10.1001/archneur.1996.00550070080014. [DOI] [PubMed] [Google Scholar]
- Weinshenker B. G., Penman M., Bass B., Ebers G. C., Rice G. P. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992 Aug;42(8):1468–1471. doi: 10.1212/wnl.42.8.1468. [DOI] [PubMed] [Google Scholar]